SCHEMBL244322

SCHEMBL244322

CC(C)c1ccc(-c2ccoc2C(=O)O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 2/20 0.43
AGTR1 P30556 1/20 0.42
AGTR2 P50052 1/20 0.42
PRKAB2 O43741 1/20 0.42
PRKAG1 P54619 1/20 0.42
PRKAA2 P54646 1/20 0.42
PRKAA1 Q13131 1/20 0.42
PRKAG3 Q9UGI9 1/20 0.42
PRKAG2 Q9UGJ0 1/20 0.42
PRKAB1 Q9Y478 1/20 0.42
FFAR1 O14842 1/20 0.41
KIF11 P52732 1/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2D6 P10635 1/20 0.39
HIF1A Q16665 1/20 0.39
MEN1 O00255 2/20 0.38
MAPT P10636 2/20 0.38
KMT2A Q03164 2/20 0.38
DHODH Q02127 2/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2318665 0.81 SMN1; SMN2 (0.42) AGTR1AGTR2PRKAB2PRKAG1PRKAA2
SCHEMBL137803 0.81 AGTR1 (0.42) AGTR1AGTR2MAPTKMT2AKDM4E
SCHEMBL2030709 0.81 AGTR1 (0.44) AGTR1AGTR2MAPTKDM4ENOTUM
SCHEMBL8138770 0.79 BCL2L1 (0.48) GPR35AGTR1AGTR2KMT2AKDM4E
SCHEMBL27605316 0.79 KMT2A (0.44) AGTR1AGTR2MEN1MAPTKMT2A
SCHEMBL3983853 0.79 HSD17B10 (0.47) AGTR1AGTR2MEN1MAPTKMT2A
SCHEMBL1549765 0.78 KMT2A (0.46) AGTR1AGTR2KMT2A
SCHEMBL27605308 0.77 PTPN1 (0.41) AGTR1AGTR2MAPTKMT2AKDM4E
SCHEMBL746600 0.74 ADRB1 (0.46)
SCHEMBL5634176 0.74 MAPK14 (0.49) AGTR1AGTR2MEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102946882-B Phenylalamine derivatives and as the purposes of non-peptide GLP-1-1 receptor modulators ARGUSINA, INC. (US) 2016-05-18 CN disclosed
US-8748412-B2 Phenylalanine derivatives and their use as non-peptide GLP-1 receptor modulators ARGUSINA BIOSCIENCE INC. (KY) 2014-06-10 US disclosed
CN-102946882-A Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators ARGUSINA INC 2013-02-27 CN disclosed
EP-2531198-A1 PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS Argusina Inc. (US) 2012-12-12 EP disclosed
US-20120004198-A1 PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS ARGUSINA INC. (US) 2012-01-05 US disclosed
WO-2011097300-A1 PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS ARGUSINA, INC. (US) 2011-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004198-A1 PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, GPR119 GPR35 102/4885AGTR1 123/4885AGTR2 240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.